Benzinga | Nov 10, 2021 06:08PM EST

Cyclacel Pharmaceuticals Q3 EPS $(0.54) Beats $(0.65) Estimate

Cyclacel Pharmaceuticals (NASDAQ:CYCC) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.65) by 16.92 percent. This is a 14.89 percent decrease over losses of $(0.47) per share from the same period last year.